Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 3/20 | 0.35 |
| ▸ | HINT1 | P49773 | 4/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30579774 | 0.85 | TGM2 (0.39) | PNPNT5E | |
| SCHEMBL31483545 | 0.83 | HINT1 (0.37) | HINT1NT5E | |
| SCHEMBL31483544 | 0.81 | HINT1 (0.37) | HINT1NT5E | |
| SCHEMBL30579769 | 0.81 | POLB (0.36) | HINT1NT5E | |
| SCHEMBL12959076 | 0.77 | PNP (0.56) | PNPHINT1TLR7HPGDMEN1 | |
| SCHEMBL12820927 | 0.77 | PNP (0.56) | PNPHINT1TLR7HPGDMEN1 | |
| SCHEMBL40998 | 0.77 | PNP (0.56) | PNPHINT1TLR7HPGDMEN1 | |
| SCHEMBL30326363 | 0.76 | PNP (0.55) | PNPHINT1TLR7HPGDMEN1 | |
| SCHEMBL31726147 | 0.75 | TLR7 (0.48) | PNPTLR7 | |
| SCHEMBL26568527 | 0.75 | PNP (0.40) | PNPHINT1TLR7NT5EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522630-B2 | MRNA cap analog and uses thereof | HANMI FINE CHEMICAL CO., LTD. (KR) | 2026-01-13 | — | — | US | disclosed |
| US-20250230183-A1 | MRNA CAP ANALOG AND USES THEREOF | HANMI FINE CHEMICAL CO., LTD. (KR) | 2025-07-17 | — | — | US | disclosed |
| EP-4506353-A1 | MRNA CAP ANALOG AND USES THEREOF | Hanmi Fine Chemical Co., Ltd. (KR) | 2025-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230183-A1 | MRNA CAP ANALOG AND USES THEREOF | RNGTT, RNMT, CAP1 | PNP 635/4885HINT1 579/4885TLR7 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.